Biodrugs

Journal Title：Biodrugs

An essential resource for R&D professionals and clinicians with an interest in biologic therapies.

BioDrugs covers the development and therapeutic application of biotechnology-based pharmaceuticals and diagnostic products for the treatment of human disease.

BioDrugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist patients, caregivers and others in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

对于对生物疗法感兴趣的研发专业人士和临床医生而言，这是必不可少的资源。

BioDrugs 涵盖用于治疗人类疾病的基于生物技术的药物和诊断产品的开发和治疗应用。

BioDrugs 提供了一系列额外的增强功能，旨在提高期刊内容的知名度、读者群和教育价值。每篇文章都附有一个关键点摘要，为广大读者提供了一个省时的内容概述。文章可能附有简单的语言摘要，以帮助患者、护理人员和其他人了解重要的医学进展。该杂志还提供了包含各种其他类型的增强功能的选项，包括幻灯片、视频和动画。所有增强功能都经过同行评审，达到与文章本身相同的高标准。同行评审是使用由国际专家数据库支持的 editorial manager® 进行的。该数据库与其他 Adis 期刊共享。

Biodrugs创刊于1994年，由ADIS INT LTD出版商出版，收稿方向涵盖免疫学 - 医学全领域，此刊是该细分领域中属于非常不错的SCI期刊，在行业细分领域中学术影响力较大，专业度认可很高，所以对原创文章要求创新性较高，如果您的文章质量很高，可以尝试。平均审稿速度>12周，或约稿，影响因子指数5.313，该期刊近期没有被列入国际期刊预警名单，广大学者值得一试。